112.16
-4.33 (-3.72%)
| Previous Close | 116.49 |
| Open | 115.76 |
| Volume | 701,239 |
| Avg. Volume (3M) | 867,245 |
| Market Cap | 5,680,679,936 |
| Price / Sales | 13.20 |
| Price / Book | 90.89 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -74.47% |
| Operating Margin (TTM) | -51.89% |
| Diluted EPS (TTM) | -5.99 |
| Quarterly Revenue Growth (YOY) | 66.00% |
| Total Debt/Equity (MRQ) | 338.43% |
| Current Ratio (MRQ) | 2.11 |
| Operating Cash Flow (TTM) | -128.41 M |
| Levered Free Cash Flow (TTM) | -28.71 M |
| Return on Assets (TTM) | -27.28% |
| Return on Equity (TTM) | -231.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Axsome Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.25 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 16.59% |
| % Held by Institutions | 79.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alethea Capital Management, Llc | 30 Sep 2024 | 738,503 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 216.00 (Mizuho, 92.58%) | Buy |
| Median | 176.00 (56.92%) | |
| Low | 150.00 (Leerink Partners, 33.74%) | Buy |
| Average | 177.31 (58.09%) | |
| Total | 13 Buy | |
| Avg. Price @ Call | 120.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 May 2025 | 180.00 (60.49%) | Buy | 116.49 |
| 03 Apr 2025 | 200.00 (78.32%) | Buy | 107.89 | |
| Baird | 06 May 2025 | 162.00 (44.44%) | Buy | 116.49 |
| 03 Mar 2025 | 160.00 (42.65%) | Buy | 127.15 | |
| Wells Fargo | 06 May 2025 | 165.00 (47.11%) | Buy | 116.49 |
| 12 Feb 2025 | 160.00 (42.65%) | Buy | 131.55 | |
| RBC Capital | 29 Apr 2025 | 193.00 (72.08%) | Buy | 109.92 |
| 19 Feb 2025 | 192.00 (71.18%) | Buy | 126.96 | |
| Jefferies | 07 Apr 2025 | 200.00 (78.32%) | Buy | 98.50 |
| Needham | 01 Apr 2025 | 153.00 (36.41%) | Buy | 111.67 |
| 03 Mar 2025 | 153.00 (36.41%) | Buy | 127.15 | |
| Mizuho | 27 Mar 2025 | 216.00 (92.58%) | Buy | 121.77 |
| 26 Feb 2025 | 212.00 (89.02%) | Buy | 128.33 | |
| Morgan Stanley | 27 Feb 2025 | 190.00 (69.40%) | Buy | 126.41 |
| Cantor Fitzgerald | 19 Feb 2025 | 153.00 (36.41%) | Buy | 126.96 |
| Truist Securities | 19 Feb 2025 | 200.00 (78.32%) | Buy | 126.96 |
| B of A Securities | 11 Feb 2025 | 167.00 (48.89%) | Buy | 132.20 |
| Deutsche Bank | 11 Feb 2025 | 176.00 (56.92%) | Buy | 132.20 |
| Leerink Partners | 10 Feb 2025 | 150.00 (33.74%) | Buy | 127.08 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |